Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.


Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

LRP/MVP (Drug Resistance Marker)

  • Product Code: X1395M
  • Size: 100 µg
  • Price (USD): $433

Cat #

X1395M		 Quantity:      

Data Sheet

Product Name

LRP/MVP (Drug Resistance Marker)


Lung-Resistance Related Protein; Major Vault Protein







Product Type

Monoclonal Antibody


Human, Rat


Gel Supershift, Flow Cytometry, Western Blot, Immunoprecipitation, Immunohistochemistry (Frozen & Paraffin Sections)


Protein A/G Chromatography


100 µg

Price (USD)



Recognizes a protein of 104kDa-110kDa, characterized as major vault protein (MVP). MVP is identical to lung-resistance related protein (LRP). Vaults are large ribonucleoprotein particles (RNPs) present in all eukaryotic cells. They have a complex morphology, including several small molecules of RNA, but a single protein species. The MVP accounts for >70% of their mass. Their shape is reminiscent of the nucleopore central plug. Amino acid 241-280 of human estrogen receptor (ER), (site of nuclear localization signal sequence), is mapped to be the site of interaction between ER and MVP. Treatment of cells with estradiol increases the amount of MVP in nuclear extract. Anti-estrogen 1C1182 shows no effect. The hormone-dependent interaction of vaults with ER is prevented in vitro by sodium molybdate. Antibodies to progesterone and glucocorticoid receptors are also able to co-immunoprecipitate the MVP. LRP is a protein overexpressed in many neoplastic tissues and cell lines. Expression of LRP predicts a poor response to chemotherapy.


Hybridoma produced by the fusion of splenocytes from mice immunized with immunoprecipitated protein from phosphocellulose column flow through of extract of human breast cancer MCF-7 cells and mouse myeloma Sp2/0-Ag14 cells.

Positive Control

SKBR-3, HeLa or MCF-7 cells, breast tumors


Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Image

Image Legend

Immunohistochemical staining using LRP/MVP antibody on formalin fixed, paraffin embedded human breast carcinoma.

Database Links:



1. Herrmann C, et al: Major vault protein of electric ray is a phosphoprotein. Neurochem Res 1998 Jan;23(1):39-46.
2. Hamill DR, Suprenant KA: Characterization of the sea urchin major vault protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. Dev Biol 1997;190(1):117-128.
3. Izquierdo MA, et al: Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996 Mar;148(3):877-887.
4. Hart SM, et al.: Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol 1997 Nov;25(12):1227-1232.
5. den Boer ML, et al: Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998 Mar 15;91(6):2092-2098.
6. Izquierdo MA, et al: Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996 Jun;32A(6):979-984.
7. Schroeijers AB, et al.: Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. Am J Pathol 1998 Feb;152(2):373-378.
8. Abbondanza C, et al: Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell. J Cell Biol 1998;141(6):1301-1310.
9. Dingemans AM, et al: Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol 1996 Aug;7(6):625-630.
10. Den Boer, M.L. et al. Relatiomship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91, 2092-2098 (1998).